ipass

Argyropoulos and Unruh (2015) published reconstructed IPASS clinical trial data. Despite being reconstructed, this data set retains all of the features shown in references, as well as full access to the observations from this clinical trial.The database spans the months of March 2006 to April 2008.The study's main goal is to compare gefitinib to carboplatin/paclitaxel doublet chemotherapy as first-line treatment in terms of progression-free survival (in months) in selected non-small-cell lung cancer (NSCLC) patients.

datasets

Flexible parametric Accelerated Hazards (AH) regression models in overall and relative survival frameworks with 13 distinct Baseline Distributions. The AH Model can also be applied to lifetime data with crossed survival curves. Any user-defined parametric distribution can be fitted, given at least an R function defining the cumulative hazard and hazard rate functions. See Chen and Wang (2000) <doi:10.1080/01621459.2000.10474236>, and Lee (2015) <doi:10.1007/s10985-015-9349-5> for more details.

Abdisalam Muse

AHSurv

Flexible Parametric Accelerated Hazards Models

ipass function

A data frame with 1217 rows and 3 variables:<ul>
<li>time: progression free survival (in months)</li>
<li>status: failure indicator (1 - failure; 0 - otherwise)</li>
<li>arm: (1 - gefitinib; 0 - carboplatin/paclitaxel doublet chemotherapy)</li>
</ul>

ipass: IRESSA Pan-Asia Study (IPASS) data set

Description

Arguments

Format

References